Novavax, Inc. (0A3S.L)
| Previous close | 58.18 |
| Open | 59.14 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 58.37 - 60.36 |
| 52-week range | 5.68 - 60.36 |
| Volume | |
| Avg. volume | 111,016 |
| Market cap | N/A |
| Beta (5Y monthly) | 1.60 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Yahoo Finance Video
Novavax stock surges after resolving Gavi vaccine dispute
Vaccine developer Novavax (NVAX) is seeing its stock skyrocket after resolving a dispute with the global nonprofit vaccine alliance Gavi. In an agreement, Novavax has refunded a large portion of Gavi's payment for COVID-19 vaccines that were not delivered. Yahoo Finance Health Reporter Anjalee Khemlani breaks down the details. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live. Editor's note: This article was written by Luke Carberry Mogan.
- Yahoo Finance Video
Novavax stock rises on Covid vaccine dispute settlement
Shares of Novavax (NVAX) are rising after the company moves to settle a dispute over a canceled Covid vaccine purchase agreement. The company will pay up to $475 million over the next 5 years to global vaccine organization, Gavi, The Vaccine Alliance. Yahoo Finance Anchors Rachelle Akuffo and Akiko Fujita break down the latest development for the company and what it means moving forward. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live. Editor's note: This article was written by Nicholas Jacobino
- Yahoo Finance
Novavax resolves Gavi dispute over COVID-19 vaccines
Novavax has resolved a potentially expensive battle with Gavi, opening up a pathway for the company to get out of the red.
